[HTML][HTML] Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski, C Devoe, S Lord… - British journal of …, 2021 - nature.com
Abstract Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective,
first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor …
first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor …
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski, C Devoe, S Lord… - British Journal of …, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia …
Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia …
[PDF][PDF] Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski, C Devoe, S Lord, J Pollard… - 2021 - academia.edu
BACKGROUND: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-
in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski… - British journal …, 2021 - mdanderson.elsevierpure.com
Background: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
[HTML][HTML] Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski, C Devoe, S Lord… - British Journal of …, 2021 - ncbi.nlm.nih.gov
Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
GI Shapiro, R Wesolowski, C Devoe, S Lord… - British Journal of …, 2021 - europepmc.org
Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski, C Devoe… - British Journal of …, 2021 - ohiostate.elsevierpure.com
Background: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
GI Shapiro, R Wesolowski, C Devoe… - British journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours.
GI Shapiro, R Wesolowski, C Devoe, S Lord… - British Journal of …, 2021 - europepmc.org
Background Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …
class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We …